New drug targets hard-to-treat KRAS mutation in advanced cancers
NCT ID NCT07456046
First seen Mar 18, 2026 · Last updated May 01, 2026 · Updated 4 times
Summary
This early-phase trial tests a new drug called D3S-003 in people with advanced solid tumors that have a specific KRAS p.G12D mutation. The study aims to find a safe dose and check for side effects. About 42 participants whose cancer has worsened after standard treatments will receive the drug to see if it can help control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS P.G12D are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
D3 Bio Investigative Site 1402
RECRUITINGSan Antonio, Texas, 78229, United States
Conditions
Explore the condition pages connected to this study.